
|Videos|March 29, 2021
Examining the Role of Frontline BTKi Monotherapy in CLL
Author(s)Jennifer R. Brown, MD, PhD
Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































